8110 Stock Chart & Stats
€3.28
€0.16(5.13%)
At close: 4:00 PM EDT
€3.28
€0.16(5.13%)
Day’s Range― - ―
52-Week Range€2.08 - €6.75
Previous CloseN/A
Volume0.00
Average Volume (3M)23.00
Market Cap
€26.57M
Enterprise Value€175.21
Total Cash (Recent Filing)€53.09M
Total Debt (Recent Filing)€41.16M
Price to Earnings (P/E)―
Beta0.92
Next Earnings
Nov 26, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-9.76
Shares Outstanding5,196,964
10 Day Avg. Volume0
30 Day Avg. Volume23
Financial Highlights & Ratios
PEG Ratio1.81
Price to Book (P/B)-0.22
Price to Sales (P/S)0.01
P/FCF Ratio1.36
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)€14.71B
Bulls Say, Bears Say
Bulls Say
Asset-light Business TransitionThe asset-light shift can reduce fixed infrastructure needs and fulfillment costs while increasing operating flexibility. A more partner-based model may support better scalability and gradually improve the economics of the platform.
Higher-margin Service GrowthGrowth in marketplace services and promotional products indicates progress toward a more diversified revenue mix. If sustained, these areas can reduce dependence on lower-margin product distribution and support stronger contribution economics.
Reduced Debt BurdenDebt reduction is a meaningful balance-sheet improvement that can lower financing pressure and preserve liquidity. Although negative equity remains a major constraint, lower absolute debt provides some additional flexibility during the business transition.
Bears Say
Persistent Negative EquityA persistently negative equity base weakens the company’s financial resilience and limits access to conventional balance-sheet support. It also raises refinancing and solvency risk, leaving less capacity to absorb operating setbacks or invest for growth.
Unreliable Cash GenerationThe return to negative operating and free cash flow shows that the company is not consistently funding operations internally. Continued cash deficits could increase dependence on external financing and constrain investment in technology, inventory, and distribution.
Contracting Revenue And Thin MarginsRevenue contraction and very thin gross margins leave limited room to absorb fulfillment, procurement, or competitive pressures. Ongoing losses indicate that operational improvements have not yet produced a sustainably profitable business model.
111 News
8110 FAQ
What was 111 Inc’s price range in the past 12 months?
111 Inc lowest stock price was €2.08 and its highest was €6.75 in the past 12 months.
What is 111 Inc’s market cap?
111 Inc’s market cap is €26.57M.
When is 111 Inc’s upcoming earnings report date?
111 Inc’s upcoming earnings report date is Nov 26, 2026 which is in 92 days.
How were 111 Inc’s earnings last quarter?
Currently, no data Available
Is 111 Inc overvalued?
According to Wall Street analysts 111 Inc’s price is currently Overvalued.
Does 111 Inc pay dividends?
111 Inc does not currently pay dividends.
What is 111 Inc’s EPS estimate?
111 Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does 111 Inc have?
111 Inc has 5,196,964 shares outstanding.
What happened to 111 Inc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of 111 Inc?
Currently, no hedge funds are holding shares in DE:8110
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
111 Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-63.97%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-22.12%
Trailing 12-Months
Company Description
111 Inc
Based in Shanghai, People's Republic of China, 111, Inc. (established in 2010 and formerly known as New Peak Group until April 2018) is a prominent entity in the Chinese healthcare sector, operating a comprehensive online-to-offline (O2O) ecosystem. Its operations are structured across both business-to-business (B2B) and business-to-consumer (B2C) channels. The company facilitates the sale of a wide array of medical and wellness products, reaching customers through its online retail channels as well as wholesale and retail pharmacy networks. This extensive product catalog encompasses prescription medications, over-the-counter drugs (both Western and traditional Chinese), dietary supplements like vitamins, optical products such as contact lenses, various medical supplies and devices (e.g., bandages, thermometers), personal care items (including skincare, birth control, and sexual wellness products), and infant care essentials. Beyond product sales, 111, Inc. provides value-added services to consumers, such as online consultation and electronic prescription fulfillment. For its business partners, the company manages an online marketplace enabling third-party vendors to directly supply pharmacies. It further supports its "1 Pharmacy" clients – comprising pharmacies and wholesalers – with online loan application services, alongside offering data and supply chain integration solutions. Its operational scope also extends to critical back-end functions, including warehousing, logistics management, procurement, research and development, consulting, as well as software development and IT support. As of December 31, 2021, its physical footprint included 14 retail pharmacies operating under the "Yi Hao Pharmacy" brand across several key regions: Guangzhou, Tianjin, Kunshan, Chongqing, and Wuhan. The company caters to a diverse clientele, encompassing individual consumers, pharmacies, pharmaceutical manufacturers and distributors, medical practitioners, and insurance providers.
Technical Analysis
Rockwell Med
―
Dyadic International
―
Rein Therapeutics
―
Elutia
―
Neuphoria Therapeutics
―











